Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Capivasertib, sold under the brand name Truqap, is an anti-cancer medication used for the treatment of breast cancer. It is taken by mouth.
Read the full article on WikipediaLocally advanced or metastatic breast cancer Clinical criteria: The condition must be human epidermal growth factor receptor 2 (HER2) negative, AND The condition must be estrogen receptor positive, AND The treatment must be in combination with fulvestrant, AND The treatment must be following progression on at least one endocrine-based regimen in the metastatic setting; OR The treatment must be following recurrence on or within 12 months of completing endocrine-based adjuvant therapy. A patient who has progressive disease when treated with this drug is no longer eligible for PBS-subsidised treatment with this drug. Confirm that the following information is documented/retained in the patient's medical records once only with the first PBS prescription: 1) Evidence of HER2 negative status (evidence obtained in relation to past PBS treatment is acceptable). 2) Evidence of HR status.
Working under the parallel aged-care framework? Aged-care equivalent →